Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 30 Jun 2004 |
| Genmab, US FDA Accepts Genmab's IND for HuMax-CD20 to Treat CLL | 21 Jun 2004 |
| Genmab, announces private placement memorandum in connection with a private placement | 18 Jun 2004 |
| Genmab, quarterly statement of shareholdings | 17 Jun 2004 |
| Genmab, current statement of shareholdings | 4 Jun 2004 |